NTRK Tempus Raises $200M in Series G2, Inks Oncology Testing Collaboration With Bayer The partners are starting by testing patients with colorectal and thyroid cancers using the 648-gene Tempus xT assay, but could expand to other areas in the future. FDA Approves Foundation Medicine CDx, Bayer's Vitrakvi for NTRK Patients The test analyzes substitutions, insertion and deletion alterations, and copy number alterations in 324 genes, along with some genomic signatures in solid tumors. Bayer, NeoGenomics Launch Free NTRK Fusion Testing Program The drugmaker will cover the cost of testing for up to 500 patients in the US with MSI-high colorectal cancer or RAI-refractory differentiated thyroid cancer. Japanese Regulator Approves Foundation Medicine CDx for Roche's Rozlytrek in Lung Cancer The approval will allow clinicians to identify NSCLC patients with ROS1 fusion genes who could benefit from treatment with Rozlytrek. Global Survey Reveals Suboptimal Molecular Testing Access in Lung Cancer Despite Broad Guidelines Premium An IASLC survey showed that molecular testing is not performed in line with expert guidelines, which means only a minority of lung cancer patients are benefitting from precision oncology. Aug 16, 2019 Foundation Medicine to Seek FDA Approval for FoundationOne as CDx to Genentech's Rozlytrek Jun 27, 2019 Japanese Regulator Approves Foundation Medicine CDx Assay for Roche's Rozlytrek May 30, 2019 Caris Life Sciences Plans Integrated Molecular Testing, Trial Matching Service With New Acquisition Premium May 16, 2019 Roche Drug Shows Benefit in Pediatric Patients With Rare, Molecularly Defined Tumors Premium Apr 2, 2019 Bayer, Loxo Next-Generation TRK Inhibitor Shows Promising Activity in AACR Study Premium Jan 8, 2019 Circulogene Broadens Push Into Companion Diagnostics with NTRK Fusion Assay Premium Nov 27, 2018 Loxo's Pan-Cancer Drug Garners FDA Approval for Patients With NTRK Fusions Oct 31, 2018 Lung Cancer Panel From PlexBio Receives CE Mark Oct 24, 2018 Almac Diagnostic Services to Build Pan-Cancer NGS Companion Test for TP Therapeutics Breaking News FDA Revises SARS-CoV-2 Test Emergency Use Authorization Requirements to Account for Variants Geisinger Wins $5M NIH Grant to Develop Point-of-Care Genetic Diagnostic Tool Second Genome, Virginia Commonwealth University Partner on NASH Biomarker Discovery LGC Receives CE Mark for AccuPlex SARS-CoV-2, Flu A/B, RSV Reference Material Kit Esophageal Cancer Testing Firm Lucid Diagnostics Files For IPO Twist Bioscience, DeepCDR Collaborate on Antibody Library Design The Scan Booster for At-Risk The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk. Preprints OK to Mention Again Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications. Hundreds of Millions More to Share The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post. Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.